论文部分内容阅读
目的:观察周剂量泰索帝联合顺铂方案治疗一线及二线晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法:2000年~2005年收治的77例ⅢB—Ⅳ期NSCLC患者,分为初治组和复治组,初治组36例,复治组41例,泰索帝35mg/m2静脉点滴1h,第1、8天,DDP40mg静脉点滴,第1~3天,21d为1周期。结果:77例中CR6例,PR19例,NC42例,PD10例。总有效率(RR)为32.5%(25/77)。初治组RR44.4%(16/36),复治组RR24.3%(10/41)。全组中位TTP为4个月(2～12个月),中位生存期13月,1年生存率为65.7%,2年生存率14.7%,主要毒副反应为骨髓抑制;白细胞下降占32.46%(25/77),Ⅲ～Ⅳ度2.59%(2/77);非血液学毒性轻微。全组无治疗相关性死亡。结论:周剂量泰索帝联合顺铂方案一线及二线治疗晚期非小细胞肺癌均疗效较好,耐受性佳。
Objective: To observe the clinical efficacy and side effects of weekly doses of taxotere combined with cisplatin in the treatment of first-line and second-line advanced non-small cell lung cancer (NSCLC). Methods: A total of 77 patients with stage ⅢB-Ⅳ NSCLC who were admitted from 2000 to 2005 were divided into two groups: primary treatment group and retreatment group, initial treatment group (36 cases), retreatment group (41 cases), Taxotere 35 mg / m2 intravenous infusion for 1 hour On the first and eighth days, DDP40mg intravenous drip, 1 to 3 days, 21d for a cycle. Results: Of the 77 cases, 6 were CR, 19 were PR, 42 were NC, and 10 were PD. The total effective rate (RR) was 32.5% (25/77). RR44.4% (16/36) in the newly diagnosed group and RR24.3% (10/41) in the retreatment group. The overall median TTP was 4 months (range 2 to 12 months). The median survival time was 13 months. The 1-year survival rate was 65.7% and the 2-year survival rate was 14.7%. The main toxicities were myelosuppression. Leukopenia 32.46% (25/77), Ⅲ ~ Ⅳ degree 2.59% (2/77); non-hematologic toxicity was mild. The whole group had no treatment-related deaths. Conclusion: The weekly dose of Taxotere combined with cisplatin in first-line and second-line treatment of advanced non-small cell lung cancer are better effective and well tolerated.